A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head trial with semaglutide (Ozempic, Wegovy).

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di ...

Discover how the tirzepatide weight loss study revealed boosted fat oxidation, appetite reduction, and key findings on metabolic adaptation resistance.

The study included a co-administered melanocortin 4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1 /GIP) tirzepatide arm, bremelanotide ...

Overall, these findings suggest that most participants receiving tirzepatide had a relatively stable weight journey over 3 years in the SURMOUNT-1 3-year study, and managed to avoid any ...

The study, referred to as Human Study #3 or GLP-1-H24-3, aimed to determine if tirzepatide, the active drug in Zepbound®, could be effectively delivered into the human bloodstream using Lexaria’s ...

The study revealed a significant reduction in adverse events with DehydraTECH-tirzepatide capsules compared to the conventional Zepbound injection.

Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose weight—without the nauseating symptoms now commonly seen with GLP-1 drugs.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at least six months lost an average of 12.9% of their body weight. The ...